ACT for Alzheimer's Disease: Supportive Regenerative Care for Indian Families | ALIV

Medically Reviewed by Dr. Sunita Tandulwadkar | Written by ALIV

Alzheimer's disease — the most common form of dementia, affecting memory, cognition, and ultimately independence — is one of the most distressing diagnoses in medicine, particularly for families who watch a loved one change progressively. The absence of disease-modifying pharmaceutical therapy in routine clinical use (beyond recently approved monoclonal antibodies that are not yet widely available or applicable in India) means that many families arrive at ALIV having exhausted standard options and seeking something additional. ALIV's ACT programme for Alzheimer's is offered with the deepest respect for this situation — and with complete honesty about what the current evidence can and cannot promise.

The ACT Mechanism in Alzheimer's Disease

Alzheimer's disease involves two key pathological processes: abnormal protein accumulation (amyloid plaques and tau tangles) and neuroinflammation driven by activated microglia. ACT does not address the protein aggregation pathology directly — no current therapy reliably does this. What ACT can target is the neuroinflammatory dimension: the MSC-derived paracrine signals (IL-10, TGF-β) reduce microglial neuroinflammation that drives ongoing neurodegeneration alongside the primary protein aggregation pathology. Additionally, neurotrophic factors (BDNF, NGF) in ACT preparations support the survival and function of remaining cholinergic neurons — the population most severely affected in Alzheimer's disease.

What Clinical Goals Are Realistic?

The realistic clinical goal is meaningful improvement in quality of life, cognitive stability, and non-cognitive symptoms (agitation, sleep disruption, apathy) rather than reversal of cognitive decline or restoration of lost memories. Some patients and families report improved alertness, improved engagement in activities, and improved mood in the months following ACT. Whether ACT produces meaningful slowing of progression — which requires a long follow-up period and comparator data to assess rigorously — is a question that current observational data from ALIV's patient cohort can inform but cannot definitively answer. This is the honest clinical position. See: ACT results timeline — what to expect.

Patient Selection and Practical Considerations

ACT for Alzheimer's is most clinically relevant in patients at mild to moderate stages (Clinical Dementia Rating 0.5–2), where residual neuronal populations are available for neurotrophic support. Patients at very advanced stages (severe dementia, CDR 3) have more limited neurological reserve and the clinical benefit from ACT is correspondingly more modest. A key practical consideration: the patient must be able to cooperate with the harvest procedure under local anaesthesia. For patients with significant agitation or very limited cooperation capacity, the harvest procedure may not be feasible. The pre-ACT consultation assesses this practical candidacy alongside clinical candidacy.

How do I discuss ACT for Alzheimer's with my loved one's neurologist?

Present ACT as an additional supportive intervention you are exploring — not as an alternative to the neurologist's management plan. Bring the ALIV clinical summary of the proposed protocol to the neurology appointment. The neurologist's perspective on the patient's disease stage, prognosis, and specific clinical picture provides essential context for determining whether ACT is appropriate for this particular patient at this particular time. Neurologist collaboration is strongly encouraged by ALIV for all Alzheimer's ACT patients.

Are there any risks specifically for Alzheimer's patients?

The primary procedure-related risks are those of the harvest procedure itself — local anaesthesia-related risks and harvest site discomfort — which are the same as for other ACT patients. There are no established specific risks for Alzheimer's patients from the ACT preparation itself. The practical risks are those of managing a cognitively impaired patient through a full procedure day — which requires careful preparation, family support, and clear communication. ALIV's team has extensive experience in supporting patients with cognitive impairment through the procedure day safely and comfortably.

Medically Reviewed by Dr. Sunita Tandulwadkar. This article is for informational purposes only and does not constitute medical advice. Therapies offered by ALIV are proprietary, experimental protocols and results vary by individual.